Search

Your search keyword '"Bölükbas, Servet"' showing total 267 results
Start Over Author "Bölükbas, Servet"
267 results on '"Bölükbas, Servet"'

2. ERASURE: early autologous blood pleurodesis for postoperative air leaks—a randomized, controlled trial comparing prophylactic autologous blood pleurodesis versus standard watch and wait treatment for postoperative air leaks following thoracoscopic anatomic lung resections

Author

Karampinis, Ioannis, Ruckes, Christian, Doerr, Fabian, Bölükbas, Servet, Ricciardi, Sara, Cardillo, Giuseppe, Galvez, Carlos, Vidmar, Bogdan, Stupnik, Tomaz, Fang, Vincent, Petersen, Rene Horsleben, and Roessner, Eric Dominic

Published
2024
Full Text
View/download PDF

3. Chylothorax

Author

Baldes, Natalie, Bölükbas, Servet, Passlick, Bernward, Section editor, Hoffmann, Hans, editor, Ludwig, Corinna, editor, and Passlick, Bernward, editor

Published
2023
Full Text
View/download PDF

6. Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome.

Author

Wiesweg, Marcel, Küter, Claudia, Schnorbach, Johannes, Keyl, Julius, Metzenmacher, Martin, Cvetkovic, Jelena, Saalfeld, Felix Carl, Glanemann, Franziska, Eberhardt, Wilfried, Oezkan, Filiz, Theegarten, Dirk, Stenzinger, Albrecht, Darwiche, Kaid, Koschel, Dirk, Herth, Felix, Bölükbas, Servet, Winter, Hauke, Weykamp, Fabian, Wermke, Martin, and Stuschke, Martin

Subjects
TREATMENT effectiveness, COMBINED modality therapy, LUNG cancer, OVERALL survival, SURVIVAL rate
Abstract

Oligometastatic (OMD) non‐small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation with local ablative therapy (LAT). However, evidence regarding the optimal choice of multimodal treatment approaches is lacking, in particular with respect to the integration of immunotherapy. This real‐world study identified 218 patients with OMD NSCLC (2004–2023, prespecified criteria: ≤5 metastases in ≤2 organ systems) from three major German comprehensive cancer centers. Most patients had one (72.5%) or two (17.4%) metastatic lesions in a single (89.9%) organ system. Overall survival (OS) was significantly longer with a single metastatic lesion (HR 0.54, p =.003), and female gender (HR 0.4, p <.001). Median OS of the full cohort was 27.8 months, with 29% survival at 5 years. Patients who had completed LAT to all NSCLC sites, typically excluding patients with early progression, had a median OS of 34.4 months (37.7% 5‐year OS rate) with a median recurrence‐free survival (RFS) of 10.9 months (13.3% at 5 years). In those patients, systemic treatment as part of first‐line therapy was associated with doubling of RFS (12.3 vs. 6.4 months, p <.001). Despite limited follow‐up of patients receiving chemo‐immunotherapy (EU approval 2018/2019), RFS was greatly improved by adding checkpoint inhibitors to chemotherapy (HR 0.44, p =.008, 2‐year RFS 51.4% vs. 15.1%). In conclusion, patients with OMD NSCLC benefitted from multimodality approaches integrating systemic therapy and local ablation of all cancer sites. A substantial proportion of patients achieved extended OS, suggesting a potential for cure that can be further augmented with the addition of immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

8. Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment—Comparison with Stage III Disease

Author

Guberina, Maja, primary, Pöttgen, Christoph, additional, Guberina, Nika, additional, Hoffmann, Christian, additional, Wiesweg, Marcel, additional, Richlitzki, Cedric, additional, Metzenmacher, Martin, additional, Aigner, Clemens, additional, Bölükbas, Servet, additional, Gauler, Thomas, additional, Eberhardt, Wilfried E. E., additional, Forsting, Michael, additional, Herrmann, Ken, additional, Theegarten, Dirk, additional, Darwiche, Kaid, additional, Jendrossek, Verena, additional, Stuschke, Martin, additional, and Schuler, Martin, additional

Published
2024
Full Text
View/download PDF

9. ERASURE:early autologous blood pleurodesis for postoperative air leaks — a randomized, controlled trial comparing prophylactic autologous blood pleurodesis versus standard watch and wait treatment for postoperative air leaks following thoracoscopic anatomic lung resections

Author

Karampinis, Ioannis, Ruckes, Christian, Doerr, Fabian, Bölükbas, Servet, Ricciardi, Sara, Cardillo, Giuseppe, Galvez, Carlos, Vidmar, Bogdan, Stupnik, Tomaz, Fang, Vincent, Petersen, Rene Horsleben, Roessner, Eric Dominic, Karampinis, Ioannis, Ruckes, Christian, Doerr, Fabian, Bölükbas, Servet, Ricciardi, Sara, Cardillo, Giuseppe, Galvez, Carlos, Vidmar, Bogdan, Stupnik, Tomaz, Fang, Vincent, Petersen, Rene Horsleben, and Roessner, Eric Dominic

Abstract

Background: The prolonged air leak is probably the most common complication following lung resections. Around 10–20% of the patients who undergo a lung resection will eventually develop a prolonged air leak. The definition of a prolonged air leak varies between an air leak, which is evident after the fifth, seventh or even tenth postoperative day to every air leak that prolongs the hospital stay. However, the postoperative hospital stay following a thoracoscopic lobectomy can be as short as 2 days, making the above definitions sound outdated. The treatment of these air leaks is also very versatile. One of the broadly accepted treatment options is the autologous blood pleurodesis or “blood patch”. The purpose of this trial is to investigate the impact of a prophylactic autologous blood pleurodesis on reducing the duration of the postoperative air leak and therefore prevent the air leak from becoming prolonged. Methods: Patients undergoing an elective thoracoscopic anatomic lung resection for primary lung cancer or metastatic disease will be eligible for recruitment. Patients with an air leak of > 100 ml/min within 6 h prior to the morning round on the second postoperative day will be eligible for inclusion in the study and randomization. Patients will be randomized to either blood pleurodesis or watchful waiting. The primary endpoint is the time to drain removal measured in full days. The trial ends on the seventh postoperative day. Discussion: The early autologous blood pleurodesis could lead to a faster cessation of the air leak and therefore to a faster removal of the drain. A faster removal of the drain would relieve the patient from all the well-known drain-associated complications (longer hospital stay, stronger postoperative pain, risk of drain-associated infection, etc.). From the economical point of view, faster drain removal would reduce the hospital costs as well as the costs associated with the care of a patient with a chest drain in an outpatient s

Published
2024

10. LIONS PREY: A New Logistic Scoring System for the Prediction of Malignant Pulmonary Nodules

Author

Doerr, Fabian, primary, Giese, Annika, additional, Höpker, Katja, additional, Menghesha, Hruy, additional, Schlachtenberger, Georg, additional, Grapatsas, Konstantinos, additional, Baldes, Natalie, additional, Baldus, Christian J., additional, Hagmeyer, Lars, additional, Fallouh, Hazem, additional, Pinto dos Santos, Daniel, additional, Bender, Edward M., additional, Quaas, Alexander, additional, Heldwein, Matthias, additional, Wahlers, Thorsten, additional, Hautzel, Hubertus, additional, Darwiche, Kaid, additional, Taube, Christian, additional, Schuler, Martin, additional, Hekmat, Khosro, additional, and Bölükbas, Servet, additional

Published
2024
Full Text
View/download PDF

11. Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients

Author

Doerr, Fabian, primary, Leschczyk, Tobias, additional, Grapatsas, Konstantinos, additional, Menghesha, Hruy, additional, Baldes, Natalie, additional, Schlachtenberger, Georg, additional, Heldwein, Matthias B., additional, Michel, Maximilian, additional, Quaas, Alexander, additional, Hagmeyer, Lars, additional, Höpker, Katja, additional, Wahlers, Thorsten, additional, Darwiche, Kaid, additional, Taube, Christian, additional, Schuler, Martin, additional, Hekmat, Khosro, additional, and Bölükbas, Servet, additional

Published
2024
Full Text
View/download PDF

12. Fibroblast Activation Protein–Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.

Author

Kessler, Lukas, Schwaning, Felix, Metzenmacher, Martin, Pabst, Kim, Siveke, Jens, Trajkovic-Arsic, Marija, Schaarschmidt, Benedikt, Wiesweg, Marcel, Aigner, Clemens, Plönes, Till, Darwiche, Kaid, Bölükbas, Servet, Stuschke, Martin, Umutlu, Lale, Nader, Michael, Theegarten, Dirk, Hamacher, Rainer, Eberhardt, Wilfried E.E., Schuler, Martin, and Herrmann, Ken

Published
2024
Full Text
View/download PDF

13. Theranostics with somatostatin receptor antagonists in SCLC: Correlation of 68Ga-SSO120 PET with immunohistochemistry and survival.

Author

Mavroeidi, Ilektra Antonia, Romanowicz, Anna, Haake, Tristan, Wienker, Johannes, Metzenmacher, Martin, Darwiche, Kaid, Oezkan, Filiz, Bölükbas, Servet, Stuschke, Martin, Umutlu, Lale, Opitz, Marcel, Nader, Michael, Hamacher, Rainer, Siveke, Jens, Winantea, Jane, Fendler, Wolfgang P., Wiesweg, Marcel, Eberhardt, Wilfried E. E., Herrmann, Ken, and Theegarten, Dirk

Published
2024
Full Text
View/download PDF

14. Closing the RCT Gap—A Large Meta-Analysis on the Role of Surgery in Stage I–III Small Cell Lung Cancer Patients.

Author

Doerr, Fabian, Stange, Sebastian, Salamon, Sophie, Grapatsas, Konstantinos, Baldes, Natalie, Michel, Maximilian, Menghesha, Hruy, Schlachtenberger, Georg, Heldwein, Matthias B., Hagmeyer, Lars, Wolf, Jürgen, Roessner, Eric D., Wahlers, Thorsten, Schuler, Martin, Hekmat, Khosro, and Bölükbas, Servet

Subjects
TREATMENT of lung tumors, META-analysis, DESCRIPTIVE statistics, SYSTEMATIC reviews, LUNG tumors, INFERENTIAL statistics, SMALL cell carcinoma, TUMOR classification, SURVIVAL analysis (Biometry), REGRESSION analysis
Abstract

Simple Summary: Despite guidelines recommending surgery as part of treatment for stage I small cell lung cancer (SCLC), its application remains inconsistent, and its role in stages II and III is under debate. In absence of current randomized control trials this meta-analysis compared surgery to non-surgical treatment for stages I to III SCLC. After a systematic review, ten studies with a total of 95,323 patients were analyzed. The analysis found no significant differences in patient characteristics between the surgery and non-surgery groups. The 5-year survival rate for resected patients was significantly higher compared to non-surgically treated patients. This finding was valid also for patients in stages II and III. Surgery might significantly improve survival in SCLC patients and should be considered in treatment planning even in higher stages. Introduction: Despite clear guideline recommendations, surgery is not consistently carried out as part of multimodal therapy in stage I small cell lung cancer (SCLC) patients. The role of surgery in stages II and III is even more controversial. In the absence of current randomized control trials (RCT), we performed a meta-analysis comparing surgery versus non-surgical treatment in stage I to III SCLC patients. Methods: A systematic review of the literature was conducted on 1 July 2023, focusing on studies pertaining to the impact of surgery on small cell lung cancer (SCLC). These studies were evaluated using the ROBINS-I tool. Statistical analyses, including I² tests, Q-statistics, DerSimonian-Laird tests, and Egger regression, were performed to assess the data. In addition, 5-year survival rates were analyzed. The meta-analysis was conducted according to PRISMA standards. Results: Among the 6826 records identified, 10 original studies encompassing a collective cohort of 95,323 patients were incorporated into this meta-analysis. Heterogeneity was observed across the included studies, with no discernible indication of publication bias. Analysis of patient characteristics revealed no significant differences between the two groups (p-value > 0.05). The 5-year survival rates in a combined analysis of patients in stages I–III were 39.6 ± 15.3% for the 'surgery group' and 16.7 ± 12.7% for the 'non-surgery group' (p-value < 0.0001). SCLC patients in stages II and III treated outside the guideline with surgery had a significantly better 5-year survival compared to non-surgery controls (36.3 ± 20.2% vs. 20.2 ± 17.0%; p-value = 0.043). Conclusions: In the absence of current RCTs, this meta-analysis provides robust suggestions that surgery might significantly improve survival in all SCLC stages. Non-surgical therapy could lead to a shortening of life. The feasibility of surgery in non-metastatic SCLC should always be evaluated as part of a multimodal treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Pneumonectomy for Primary Lung Tumors and Pulmonary Metastases: A Comprehensive Study of Postoperative Morbidity, Early Mortality, and Preoperative Clinical Prognostic Factors

Author

Grapatsas, Konstantinos, primary, Menghesha, Hruy, additional, Dörr, Fabian, additional, Baldes, Natalie, additional, Schuler, Martin, additional, Stuschke, Martin, additional, Darwiche, Kaid, additional, Taube, Christian, additional, and Bölükbas, Servet, additional

Published
2023
Full Text
View/download PDF

17. New Prognostic Score (Essen Score) to Predict Postoperative Morbidity after Resection of Lung Metastases

Author

Grapatsas, Konstantinos, primary, Dörr, Fabian, additional, Menghesha, Hruy, additional, Schuler, Martin, additional, Grünwald, Viktor, additional, Bauer, Sebastian, additional, Schmidt, Hartmut H. -J., additional, Lang, Stephan, additional, Kimmig, Rainer, additional, Kasper, Stefan, additional, Baldes, Natalie, additional, and Bölükbas, Servet, additional

Published
2023
Full Text
View/download PDF

19. 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

Author

Kersting, David, primary, Sandach, Patrick, additional, Sraieb, Miriam, additional, Wiesweg, Marcel, additional, Metzenmacher, Martin, additional, Darwiche, Kaid, additional, Oezkan, Filiz, additional, Bölükbas, Servet, additional, Stuschke, Martin, additional, Umutlu, Lale, additional, Nader, Michael, additional, Hamacher, Rainer, additional, Fendler, Wolfgang P., additional, Wienker, Johannes, additional, Eberhardt, Wilfried E.E., additional, Schuler, Martin, additional, Herrmann, Ken, additional, and Hautzel, Hubertus, additional

Published
2023
Full Text
View/download PDF

27. The impact of thymectomy in subgroups of Myasthenia gravis patients: a single center longitudinal observation.

Author

Menghesha, Hruy, Schroeter, Michael, Nelke, Christopher, Ruck, Tobias, Schlachtenberger, Georg, Welskop, Clara, Camo, Amina, Heldwein, Matthias, Bennink, Gerardus, Wahlers, Thorsten, Bölükbas, Servet, Doerr, Fabian, and Hekmat, Khosro

Subjects
MYASTHENIA gravis, THYMECTOMY, NEUROMUSCULAR diseases, CHOLINERGIC receptors, RECEPTOR antibodies, IMMUNOSUPPRESSIVE agents
Abstract

Background: Myasthenia gravis (MG) is a rare neuromuscular disorder. Symptoms can range from ptosis only to life threatening myasthenic crisis. Thymectomy is recommended for anti-acetylcholine receptor-antibody positive patients with early-onset MG. Here, we investigated prognostic factors shaping therapeutic outcomes of thymectomy to improve patient stratification. Methods: We retrospectively collected single-center data from a specialized center for MG from all consecutive adult patients that underwent thymectomy from 01/2012 to 12/2020. We selected patients with thymoma-associated and non-thymomatous MG for further investigations. We analyzed the patient collective regarding perioperative parameters in relation to the surgical approach. Furthermore, we investigated the dynamics of the anti-acetylcholine receptor-antibody titers and concurrent immunosuppressive therapies, as well as the therapeutic outcomes in dependence of clinical classifications. Results: Of 137 patients 94 were included for further analysis. We used a minimally invasive approach in 73 patients, whereas 21 patients underwent sternotomy. A total of 45 patients were classified as early-onset MG (EOMG), 28 as late-onset MG (LOMG) and 21 as thymoma-associated MG (TAMG). The groups differed in terms of age at diagnosis (EOMG: 31.1 ± 12.2 years; LOMG: 59.8 ± 13.7 years; TAMG: 58.6 ± 16.7 years; p < 0.001). Patients with EOMG and TAMG were more often female than patients in the LOMG group (EOMG: 75.6%; LOMG: 42.9%; TAMG: 61.9%; p = 0.018). There were no significant differences in outcome scores (quantitative MG; MG activities of daily living; MG Quality of Live) with a median follow-up of 46 months. However, Complete Stable Remission was achieved significantly more frequently in the EOMG group than in the other two groups (p = 0.031). At the same time, symptoms seem to improve similarly in all three groups (p = 0.25). Conclusion: Our study confirms the benefit of thymectomy in the therapy of MG. Both, the concentration of acetylcholine receptor antibodies and the necessary dosage of cortisone therapy show a continuous regression after thymectomy in the overall cohort. Beyond EOMG, groups of LOMG and thymomatous MG responded to thymectomy as well, but therapy success was less pronounced and delayed compared to the EOMG subgroup. Thymectomy is a mainstay of MG therapy to be considered in all subgroups of MG patients investigated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Expert consensus on resection of chest wall tumors and chest wall reconstruction

Author

Wang, Lei, primary, Yan, Xiaolong, additional, Zhao, Jinbo, additional, Chen, Chang, additional, Chen, Chun, additional, Chen, Jun, additional, Chen, Ke-Neng, additional, Cao, Tiesheng, additional, Chen, Ming-Wu, additional, Duan, Hongbin, additional, Fan, Junqiang, additional, Fu, Junke, additional, Gao, Shugeng, additional, Guo, Hui, additional, Guo, Shiping, additional, Guo, Wei, additional, Han, Yongtao, additional, Jiang, Ge-Ning, additional, Jiang, Hongjing, additional, Jiao, Wen-Jie, additional, Kang, Mingqiang, additional, Leng, Xuefeng, additional, Li, He-Cheng, additional, Li, Jing, additional, Li, Jian, additional, Li, Shao-Min, additional, Li, Shuben, additional, Li, Zhigang, additional, Li, Zhongcheng, additional, Liang, Chaoyang, additional, Mao, Nai-Quan, additional, Mei, Hong, additional, Sun, Daqiang, additional, Wang, Dong, additional, Wang, Luming, additional, Wang, Qun, additional, Wang, Shumin, additional, Wang, Tianhu, additional, Liu, Lunxu, additional, Xiao, Gaoming, additional, Xu, Shidong, additional, Yang, Jinliang, additional, Ye, Ting, additional, Zhang, Guangjian, additional, Zhang, Linyou, additional, Zhao, Guofang, additional, Zhao, Jun, additional, Zhong, Wen-Zhao, additional, Zhu, Yuming, additional, Hulsewé, Karel W. E., additional, Vissers, Yvonne L. J., additional, Loos, Erik R. de, additional, Jeong, Jin Yong, additional, Marulli, Giuseppe, additional, Sandri, Alberto, additional, Sziklavari, Zsolt, additional, Vannucci, Jacopo, additional, Ampollini, Luca, additional, Ueda, Yuichiro, additional, Liu, Chaozong, additional, Bille, Andrea, additional, Hamaji, Masatsugu, additional, Aramini, Beatrice, additional, Inci, Ilhan, additional, Pompili, Cecilia, additional, Van Veer, Hans, additional, Fiorelli, Alfonso, additional, Sara, Ricciardi, additional, Sarkaria, Inderpal S., additional, Davoli, Fabio, additional, Kuroda, Hiroaki, additional, Bölükbas, Servet, additional, Li, Xiao-Fei, additional, Huang, Lijun, additional, and Jiang, Tao, additional

Published
2021
Full Text
View/download PDF

37. Derivation and validation of a nomogram model for pulmonary thromboembolism in patients undergoing lung cancer surgery

Author

Li, Yuping, Shen, Lei, Ding, Junrong, Xie, Dong, Yang, Jian, Zhao, Yanfeng, Carretta, Angelo, Petersen, René Horsleben, Gilbert, Sebastien, Hida, Yasuhiro, Bölükbas, Servet, Fernando, Hiran C, Jiang, Gening, Zhu, Yuming, Li, Yuping, Shen, Lei, Ding, Junrong, Xie, Dong, Yang, Jian, Zhao, Yanfeng, Carretta, Angelo, Petersen, René Horsleben, Gilbert, Sebastien, Hida, Yasuhiro, Bölükbas, Servet, Fernando, Hiran C, Jiang, Gening, and Zhu, Yuming

Abstract

Background: A specific risk-stratification tool is needed to facilitate safe and cost-effective approaches to the prophylaxis of acute pulmonary thromboembolism (PTE) in lung cancer surgery patients. This study aimed to develop and validate a simple nomogram model for the prediction of PTE after lung cancer surgery using readily obtainable clinical characteristics.Methods: A total of 14,427 consecutive adult patients who underwent lung cancer surgery between January 2015 and July 2018 in our institution were retrospectively reviewed. Included in the cohort were 136 patients who developed PTE and 544 non-PTE patients. The patients were randomly divided into the derivation group (70%, 95 PTE patients and 380 non-PTE patients) and the validation group (30%, 41 PTE patients and 164 non-PTE patients). A nomogram model was developed based on the results of multivariate logistic analysis in the derivation group. The cut-off values were defined using Youden's index. The prognostic accuracy was measured by area under the curve (AUC) values.Results: In the derivation group, multivariate logistic analysis was carried out to evaluate the risk score. The risk assessment model contained five variables: age [95% confidence interval (CI): 1.008-1.083, P=0.016], body mass index (95% CI: 1.077-1.319, P=0.001), operation time (95% CI: 1.002-1.014, P=0.008), the serum level of cancer antigen 15-3 (CA15-3) before surgery (95% CI: 1.019-1.111, P=0.005), and the abnormal results of compression venous ultrasonography before surgery (95% CI: 2.819-18.838, P<0.001). All of them were independent risk factors of PTE. To simplify the risk assessment model, a nomogram model was established, which showed a good predictive performance in the derivation group (AUC 0.792, 95% CI: 0.734-0.853) and in the validation group (AUC 0.813, 95% CI: 0.737-0.890).Conclusions: A high-performance nomogram was established on the risk factors for PTE in patients undergoing lung cancer su

Published
2021

38. Derivation and validation of a nomogram model for pulmonary thromboembolism in patients undergoing lung cancer surgery

Author

Li, Yuping, primary, Shen, Lei, additional, Ding, Junrong, additional, Xie, Dong, additional, Yang, Jian, additional, Zhao, Yanfeng, additional, Carretta, Angelo, additional, Petersen, René Horsleben, additional, Gilbert, Sebastien, additional, Hida, Yasuhiro, additional, Bölükbas, Servet, additional, Fernando, Hiran C., additional, Jiang, Gening, additional, and Zhu, Yuming, additional

Published
2021
Full Text
View/download PDF

40. Roboterassistierte Lungenchirurgie

Author

Cheufou, Danjouma, additional, Baldes, Natalie, additional, Lechner, Sebastian, additional, Möller, Thorben, additional, Steinert, Matthias, additional, and Bölükbas, Servet, additional

Published
2021
Full Text
View/download PDF

44. Exploring consensus for the optimal sealant use to prevent air leak following lung surgery: a modified Delphi survey from The European Society of Thoracic Surgeons

Author

Brunelli, Alessandro, primary, Bölükbas, Servet, additional, Falcoz, Pierre Emmanuel, additional, Hansen, Henrik, additional, Jimenez, Marcelo F., additional, Lardinois, Didier, additional, Scarci, Marco, additional, Viti, Andrea, additional, Walker, Ian, additional, and Warren, Tim, additional

Published
2020
Full Text
View/download PDF

47. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

Author

Opitz, Isabelle, primary, Scherpereel, Arnaud, additional, Berghmans, Thierry, additional, Psallidas, Ioannis, additional, Glatzer, Markus, additional, Rigau, David, additional, Astoul, Philippe, additional, Bölükbas, Servet, additional, Boyd, Jeanette, additional, Coolen, Johan, additional, De Bondt, Charlotte, additional, De Ruysscher, Dirk, additional, Durieux, Valerie, additional, Faivre-Finn, Corinne, additional, Fennell, Dean A, additional, Galateau-Salle, Francoise, additional, Greillier, Laurent, additional, Hoda, Mir Ali, additional, Klepetko, Walter, additional, Lacourt, Aude, additional, McElnay, Phil, additional, Maskell, Nick A, additional, Mutti, Luciano, additional, Pairon, Jean-Claude, additional, Van Schil, Paul, additional, van Meerbeeck, Jan P, additional, Waller, David, additional, Weder, Walter, additional, Putora, Paul Martin, additional, and Cardillo, Giuseppe, additional

Published
2020
Full Text
View/download PDF

48. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

Author

Scherpereel, Arnaud, primary, Opitz, Isabelle, additional, Berghmans, Thierry, additional, Psallidas, Ioannis, additional, Glatzer, Markus, additional, Rigau, David, additional, Astoul, Philippe, additional, Bölükbas, Servet, additional, Boyd, Jeanette, additional, Coolen, Johan, additional, De Bondt, Charlotte, additional, De Ruysscher, Dirk, additional, Durieux, Valerie, additional, Faivre-Finn, Corinne, additional, Fennell, Dean, additional, Galateau-Salle, Francoise, additional, Greillier, Laurent, additional, Hoda, Mir Ali, additional, Klepetko, Walter, additional, Lacourt, Aude, additional, McElnay, Phil, additional, Maskell, Nick A., additional, Mutti, Luciano, additional, Pairon, Jean-Claude, additional, Van Schil, Paul, additional, van Meerbeeck, Jan P., additional, Waller, David, additional, Weder, Walter, additional, Cardillo, Giuseppe, additional, and Putora, Paul Martin, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results